The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer

被引：0

作者：

Andrieu, Charlotte

Al-Sultan, Dalal

Ivers, Laura

Pina, Jose Javier Berenguer

Skrobo, Darko

Ballot, Josephine

Eustace, Alex J.

Gullo, Giuseppe

Crown, John

机构：

[1] Dublin City Univ, Sch Biotechnol, Natl Inst Cellular Biotechnol, Dublin, Ireland

[2] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland

[3] CCRT Caroline Fdn, Dublin, Ireland

[4] Galway Univ Hosp, Dept Histopathol, Galway, Ireland

[5] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland

[6] St Vincents Univ Hosp, Dept Pathol, Dublin, Ireland

[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1016

引用

页数：1

共 50 条

[31] Very long response with trastuzumab for metastatic Her2-positive breast cancer
Lai-Tiong, F.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
[32] Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity
Reactions Weekly, 2020, 1794 (1) : 12 - 12
[33] Her2+metastatic gastric cancer, treated with biological Therapy -Trastuzumab/Herceptin - case report
Fratila, Ovidiucristian
Mihutiu, Simona
Ilias, Tiberiaioana
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 668 - 668
[34] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
Gullo, G.
Bettio, D.
Zuradelli, M.
Giordano, L.
Masci, G.
Bareggi, C.
Salvini, P.
Venci, A.
Santoro, A.
ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
[35] Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+metastatic breast cancer
Lu, C. Y.
Srasuebkul, P.
Drew, A. K.
Ward, R. L.
Pearson, S. -A.
INTERNAL MEDICINE JOURNAL, 2012, 42 (11) : 1229 - 1235
[36] What to do with trastuzumab therapy after achieving radiological complete remission (rCR) in HER2+metastatic breast cancer (MBC)?
Steenbruggen, T. G.
Bouwer, N. I.
Smorenburg, C. H.
Rier, H. N.
Jager, A.
Beelen, K. J.
ten Tije, A. J.
de Jong, P. C.
Drooger, J. C.
Holterhues, C.
Horlings, H. M.
Sanders, J.
Levin, M-D
Sonke, G. S.
CANCER RESEARCH, 2019, 79 (04)
[37] Estimated life years saved with trastuzumab in first-line HER2+metastatic breast cancer from 1999 to 2013
Danese, Mark
Lalia, Deepe
Brammer, Melissa
Santos, Eduardo
Lee, Abraham
Masaquel, Anthony
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T)
Luis, Ines Maria Vaz Duarte
Oh, Coyin
Wang, Zhigang
Dipiro, Pamela
Macrae, Erin Macrae
Painter, Corrie
Kryukov, Gregory
Krop, Ian E.
Winer, Eric P.
Lin, Nancy U.
Wagle, Nikhil
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[39] Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+Metastatic Breast Cancer: The DE-REAL Study
Botticelli, Andrea
Caputo, Roberta
Scagnoli, Simone
Pisegna, Simona
De Laurentiis, Michelino
Curigliano, Giuseppe
Lambertini, Matteo
Pantano, Francesco
Palazzo, Antonella
Paris, Ida
Vernieri, Claudio
Tedesco, Beatrice
Giampaglia, Marianna
Palleschi, Michela
Ballatore, Zelmira
Alesini, Daniele
D'Auria, Giuliana
Fabbri, Agnese
Rossi, Luigi
Verrazzo, Annarita
Scafetta, Roberta
Marinelli, Daniele
Sposetti, Caterina
Barberi, Vittoria
Strigari, Lidia
Marchetti, Paolo
Santini, Daniele
Fabi, Alessandra
ONCOLOGIST, 2024, 29 (04): : 303 - 310
[40] Long term HER2+metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA
Spano, J. -P.
Beuzeboc, P.
Coeffic, D.
Arnould, L.
Lortholary, A.
Andre, F.
Ferrero, J. -M.
BREAST, 2015, 24 (04): : 376 - 383

← 1 2 3 4 5 →